Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of GTx-758 (Capesaris) in castration-resistant prostate cancer
2012-004825-26Phase 2Completed
- Sponsor
- GTx
- Start
- Dec 2012
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GTx-758 in prostate cancer (PCa), sponsored by GTx. Primary endpoint: Serum PSA response at Day 90. Started Dec 2012; status: completed.
02
Drugs
GTx-758
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2012-004825-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004825-26.